ArticleVeterinary clinical pathology2025
Diagnostic Sensitivity of the PCR for Antigen Receptor Rearrangement (PARR) Assay for Canine Plasma Cell Tumors.
Article in Veterinary clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PCR for Antigen Receptor Rearrangement (PARR) assay assesses clonality of a lymphoid population. Studies suggest PARR has decreased sensitivity for detecting clonality in canine plasma cell tumors (PCT) compared to lymphoma.
objectiveAssess sensitivity of PARR assays targeting the immunoglobulin heavy chain (IGH), immunoglobulin lambda light chain (IGL), and kappa deleting element (Kde) loci in canine PCT.
methodsCanine cases included 35 PCTs (multiple myeloma and extramedullary, cutaneous or oral PCTs), 5 non-PCT foil cases, and 40 B-cell lymphoma cases. PCT diagnoses were confirmed via CD3, PAX5, and MUM1 immunolabeling, and some additionally had histopathology, serum or urine protein electrophoresis, or immunofixation. Nodal B-cell lymphomas were diagnosed by flow cytometry. Routine PARR (targeting IGH V-D-J and D-J rearrangements) and extended PARR (targeting additional IGH genes and IGL and Kde rearrangements) were performed on cytologic specimens (PCT and foil cases) and flow cytometry aspirates (lymphoma cases). Diagnostic sensitivity was calculated.
resultsAcross both PARR assays, every PCT case with sufficient sample was interpreted as clonal and no foil cases were clonal. The routine PARR assay detected a clonal immunoglobulin rearrangement in 26/35 PCT cases (74.3%; 95% CI 56.7%-87.5%). The extended assay detected immunoglobulin gene clonality in 33/35 PCT cases (94.3%; 95% CI 80.8%-99.3%). 40/40 lymphoma cases were clonal in both the routine and extended PARR assays.
conclusionThe combined PARR assays used in this study, evaluating multiple IG loci, detected clonality in all PCTs tested, but routine PARR (targeting IGH) was less sensitive for detecting PCT clonality compared to B-cell lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.